Display options
Cite
Barra ME, Soni D, Vo KH, et al. Experience with long-term rituximab use in a multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2016;2:2055217316672100doi: 10.1177/2055217316672100.
Barra, M. E., Soni, D., Vo, K. H., Chitnis, T., & Stankiewicz, J. M. (2016). Experience with long-term rituximab use in a multiple sclerosis clinic. Multiple sclerosis journal - experimental, translational and clinical, 22055217316672100. https://doi.org/10.1177/2055217316672100
Barra, Megan E, et al. "Experience with long-term rituximab use in a multiple sclerosis clinic." Multiple sclerosis journal - experimental, translational and clinical vol. 2 (2016): 2055217316672100. doi: https://doi.org/10.1177/2055217316672100
Barra ME, Soni D, Vo KH, Chitnis T, Stankiewicz JM. Experience with long-term rituximab use in a multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2016 Oct 09;2:2055217316672100. doi: 10.1177/2055217316672100. eCollection 2016. PMID: 28607739; PMCID: PMC5433395.
Copy Download .nbib Format: NLM
Share it on

Mult Scler J Exp Transl Clin. 2016 Oct 09;2:2055217316672100. doi: 10.1177/2055217316672100. eCollection 2016.

Experience with long-term rituximab use in a multiple sclerosis clinic.

Multiple sclerosis journal - experimental, translational and clinical

Megan E Barra, Dhruv Soni, Khac Huy Vo, Tanuja Chitnis, James M Stankiewicz

Affiliations

  1. Department of Pharmacy, Brigham and Women's Hospital, USA.
  2. Partners MS Center, Brigham and Women's Hospital, USA.

PMID: 28607739 PMCID: PMC5433395 DOI: 10.1177/2055217316672100

Abstract

BACKGROUND: Rituximab is a monoclonal antibody directed at CD20 positive B-lymphocytes and a potential therapeutic option in the treatment of multiple sclerosis. The safety of recurrent dosing is not established.

OBJECTIVES: The objective of this work was to report the experience of long-term rituximab administration in a comprehensive multiple sclerosis care clinic.

METHODS: This was a single-center retrospective observational analysis of patients receiving rituximab for the treatment of multiple sclerosis from 2004 to 2015. Different dosing regimens were reviewed to determine whether frequency or dose may affect safety. CD19 and CD20 counts were collected to evaluate B-cell suppression during therapy. Relapses, magnetic resonance imaging activity and rituximab-related adverse events were collected by chart review and prospective database entry.

RESULTS: Of 107 patients included, the average duration of treatment was 33.2 months. Seventy-seven patients received recurrent rituximab dosing after initiation. CD19/20 reconstitution occurred in approximately 20% of patients at 6 months, regardless of dosing strategy. Despite CD19/20 counts of 0, three patients had relapses or magnetic resonance imaging activity. Mostly mild side effects in relation to therapy were seen, with the exception of three patients requiring hospitalization for urinary tract infections.

CONCLUSIONS: In our clinic population, rituximab was well tolerated and safe with recurrent administration.

Keywords: Multiple sclerosis; long-term; rituximab; safety

References

  1. Neurology. 2014 Feb 18;82(7):573-81 - PubMed
  2. Neurology. 2008 Jun 3;70(23):2252-60 - PubMed
  3. Swiss Med Wkly. 2010 Jul 16;140:w13073 - PubMed
  4. Acta Neurol Scand. 2008 Jun;117(6):399-403 - PubMed
  5. N Engl J Med. 2008 Feb 14;358(7):676-88 - PubMed
  6. Mult Scler. 2012 Jul;18(7):1022-6 - PubMed
  7. Arthritis Rheum. 2007 Dec;56(12):3896-908 - PubMed
  8. J Rheumatol. 2015 Oct;42(10):1761-6 - PubMed
  9. Nat Rev Neurol. 2012 Nov 5;8(11):613-23 - PubMed
  10. Neurology. 2011 Apr 12;76(15):1310-5 - PubMed
  11. J Neurol. 2015 May;262(5):1115-9 - PubMed
  12. Arthritis Rheum. 2010 Sep;62(9):2625-32 - PubMed
  13. Annu Rev Immunol. 2006;24:467-96 - PubMed
  14. J Rheumatol. 2010 May;37(5):917-27 - PubMed
  15. JAMA Neurol. 2015 Sep;72(9):989-95 - PubMed
  16. Arch Neurol. 2011 Nov;68(11):1412-20 - PubMed

Publication Types